EGFR and neoplasm: For instance, studies have demonstrated that following EGFR-TKI therapy, tumor cells transition into a drug-tolerant persistent state, characterized by distinct gene expression profiles, including the upregulation of the anti-apoptotic protein BCL-XL [38].